Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Structure Therapeutics Licenses GLP-1 Patents to Roche for $100 Million Upfront

Fineline Cube Jan 8, 2026
Company Deals

Ikarovec and VectorBuilder Sign $1 Billion AAV Capsid Deal for AMD Gene Therapy

Fineline Cube Jan 8, 2026
Company Deals

Mabwell Partners with Sentonix on Neurodegenerative Disease Drug Discovery Alliance

Fineline Cube Jan 8, 2026
Company Deals

Amgen Acquires Dark Blue Therapeutics for $840 Million to Expand AML Portfolio

Fineline Cube Jan 8, 2026
Company Deals

Lilly Nears $1 Billion Deal for Ventyx’s IBD Pipeline

Fineline Cube Jan 7, 2026
Policy / Regulatory

NMPA Releases Draft 102nd Reference Preparations List for Generic Drugs

Fineline Cube Jan 6, 2026
Company Drug

Sichuan Biokin’s BL-B01D1 ADC Wins Priority Review for ESCC in China

Fineline Cube Jan 8, 2026
Company Drug

Zai Lab’s Repotrectinib Wins NMPA sNDA for NTRK Fusion-Positive Solid Tumors

Fineline Cube Jan 8, 2026
Company Drug

Suzhou GenAssist’s GEN6050X Receives FDA Clearance for Duchenne Muscular Dystrophy Treatment

Fineline Cube Mar 7, 2025

China-based Suzhou GenAssist Therapeutic Co., Ltd has announced receiving clearance from the US Food and...

Company Drug

BioRay Biopharmaceutical’s BR111 Receives NMPA Clearance for Clinical Trials in ROR1-Positive Malignancies

Fineline Cube Mar 7, 2025

Zhejiang-based BioRay Biopharmaceutical has announced receiving clearance from the National Medical Products Administration (NMPA) to...

Company Drug

CStone Pharmaceuticals’ CS5001 Enters Phase Ib Trial for Diffuse Large B-Cell Lymphoma

Fineline Cube Mar 6, 2025

China-based CStone Pharmaceuticals (HKG: 2616) has announced a Phase Ib clinical filing in Australia for...

Company Drug

Roche’s Gazyva Receives FDA Review Acceptance for Lupus Nephritis Treatment

Fineline Cube Mar 6, 2025

Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) has announced that the US Food and...

Company Drug

Ascentage Pharma’s Olverembatinib Receives Third BTD in China for Ph+ ALL Treatment

Fineline Cube Mar 6, 2025

China-based Ascentage Pharma (HKG: 6855) has announced that the Center for Drug Evaluation (CDE) of...

Company Drug

ImmuneOnco’s Timdarpacept (IMM01) and IMM2510 Receive NMPA Approval for Clinical Study in Advanced Malignant Tumors

Fineline Cube Mar 6, 2025

China-based ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG: 1541) has received approval from the National Medical Products...

Company Drug

CSPC Pharma’s JMT108 Receives NMPA Clinical Approval for Advanced Malignant Tumors

Fineline Cube Mar 6, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced clinical approval from the National Medical...

Company

Sandoz’s Q4 2024 Results Show Strong Biosimilar Growth

Fineline Cube Mar 6, 2025

Switzerland-headquartered Sandoz (SWX: SDZ) has released its Q4 2024 financial results. The firm’s global revenues...

Company Medical Device

Peijia Medical Completes First Two Implants of Trilogy THV System in Taiwan

Fineline Cube Mar 6, 2025

China’s Peijia Medical Ltd (HKG: 9996) announced the completion of the first two implant surgeries...

Company Medical Device

Huadong Medicine’s V30 Optical Radiofrequency Device Receives NMPA Review Approval

Fineline Cube Mar 6, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that the National Medical Products Administration (NMPA)...

Company Deals

Jiangsu Nhwa Pharmaceutical Invests in NeuroThree to Develop CNS Therapies

Fineline Cube Mar 6, 2025

China-based Jiangsu Nhwa Pharmaceutical Co., Ltd (SHE: 002262) announced plans to subscribe to Hong Kong-headquartered...

Company

Bayer Posts Steady Q4 Growth, Pharmaceutical Sales Lead the Way

Fineline Cube Mar 6, 2025

German giant Bayer (ETR: BAYN) has released its Q4 2024 financial results, reporting a 0.7%...

Company

NovoCare Pharmacy Offers Reduced-Cost Wegovy for Cash-Paying Patients

Fineline Cube Mar 6, 2025

Denmark-based Novo Nordisk A/S (NYSE: NVO) has announced the launch of NovoCare Pharmacy, a direct-to-patient...

Company Drug

Antengene’s Xpovio Receives Marketing Approval in Indonesia

Fineline Cube Mar 6, 2025

China-based biopharma Antengene Corp., Ltd (HKG: 6996) announced receiving marketing approval in Indonesia for its...

Company Medical Device

Sino Medical Sciences’ HT Supreme Stent System Gains Vietnamese Marketing Approval

Fineline Cube Mar 6, 2025

China-based Sino Medical Sciences Technology Inc., (SHA: 688108) announced that it has received marketing approval...

Company Deals

Yifan Pharma Secures Rights to Bayer’s Stivarga and Nexavar in China

Fineline Cube Mar 6, 2025

China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced a commercialization agreement with Bayer (ETR: BAYN),...

Policy / Regulatory

Major Policy Directions in China’s Healthcare Arena: A Comprehensive Breakdown

Fineline Cube Mar 6, 2025

In a momentous address at the Third Session of the 14th National People’s Congress on...

Company Drug

RongCan Biotech’s mRNA HPV Vaccine Receives FDA Clinical Approval

Fineline Cube Mar 6, 2025

China-based mRNA specialist RongCan (Shanghai) Biotech Co., Ltd announced that it has received clinical approval...

Company Deals

Insilico Medicine and Tenacia Partner on AI-Driven CNS Therapies

Fineline Cube Mar 6, 2025

China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine has formed a partnership with compatriot firm...

Company Deals

Lexenpharm and Sun-Novo Partner on Long-Acting Asthma and COPD Drugs

Fineline Cube Mar 6, 2025

China-based Lexenpharm has formed a partnership with compatriot firm Beijing Sun-Novo Pharmaceutical Research Co., Ltd...

Posts pagination

1 … 140 141 142 … 605

Recent updates

  • Structure Therapeutics Licenses GLP-1 Patents to Roche for $100 Million Upfront
  • Sichuan Biokin’s BL-B01D1 ADC Wins Priority Review for ESCC in China
  • Ikarovec and VectorBuilder Sign $1 Billion AAV Capsid Deal for AMD Gene Therapy
  • Zai Lab’s Repotrectinib Wins NMPA sNDA for NTRK Fusion-Positive Solid Tumors
  • Mabwell Partners with Sentonix on Neurodegenerative Disease Drug Discovery Alliance
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Structure Therapeutics Licenses GLP-1 Patents to Roche for $100 Million Upfront

Company Drug

Sichuan Biokin’s BL-B01D1 ADC Wins Priority Review for ESCC in China

Company Deals

Ikarovec and VectorBuilder Sign $1 Billion AAV Capsid Deal for AMD Gene Therapy

Company Drug

Zai Lab’s Repotrectinib Wins NMPA sNDA for NTRK Fusion-Positive Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.